Positive phase 2 results reported for erenumab in the treatment of chronic migraine

Amgen announced that the company’s experimental drug, erenumab, has met the midstage goal of a placebo-controlled, Phase II study by reducing the number of migraine attacks per month in people with chronic migraine.

Erenumab, also known as AMG 334, is a fully human monoclonal antibody that targets the Calcitonin-Gene-Related-Petitide (CGRP) receptor.

The study was conducted over 12 weeks with 667 patients who experienced approximately 18 migraine days each month.

Patients receiving 70mg or 140mg doses via subcutaneous injection once a month experienced a reduction of 6.6 migraine days per month compared to a reduction of 4.2 migraine days in those receiving placebo. The results were found to be statistically significant.

The most common side effects were were pain at the injection site, upper respiratory tract infection, and nausea. No side effects were reported in more than 5% of patients receiving erenumab.

Additional data from the study are expected to be released later this year. 1-3

View References

Comments

View Comments (3)

Poll